Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

India Stocks Advance as Early Vaccine Trials Show Promise

Published 2020-07-21, 12:42 a/m
© Bloomberg. Pedestrians stand outside the Bombay Stock Exchange (BSE) building in Mumbai, India, on Monday, May 20, 2019. Indian stocks rallied the most in more than three years and the rupee and sovereign bonds climbed after exit polls signaled Prime Minister Narendra Modi’s ruling coalition is poised to retain power. Photographer: Dhiraj Singh/Bloomberg
PFE
-
UL
-
AZN
-
BSESN
-
BNTX
-

(Bloomberg) -- India stocks advanced, tracking Asian peers, as promising results in early trials for a coronavirus vaccine and a positive start to local companies’ earnings season bolstered optimism.

The S&P BSE Sensex climbed 0.9% to 37,766.99 as of 10:10 a.m. in Mumbai, set for a fifth straight session of gains that’s taken it above its 200-day moving average. The NSE Nifty 50 Index added 0.9% and has also breached the technical indicator, forming a pattern that some investors read as a signal that gains can continue.

Both measures have jumped more than 40% from a March low, while India’s economy heads for its first recession in 40 years after business all but stalled due to a nationwide lockdown. Individual investors have turned to equities for returns, even as foreign investors have sold net $437.5 million of shares this month through Friday.

“It is only in equities -- that with some risk -- one can make some returns as other asset classes aren’t performing well in these times,” said Chokkalingam G, head of the investment advisory at Equinomics Research & Advisory Pvt. in Mumbai. “The positive news on vaccine trials has added more impetus.”

While the spread of coronavirus has seen India emerge as host of the third-highest number of infections in the world, a vaccine under development by the University of Oxford and AstraZeneca (NYSE:AZN) Plc showed promising results in early human testing. China’s CanSino Biologics Inc. and a partnership of Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) also delivered positive trial updates.

With earnings season underway, four of the six Nifty 50 companies that have announced the April-June quarterly results so far have either beaten or met analyst estimates on profits. Axis Bank Ltd., Hindustan Unilever (NYSE:UL) Ltd. and Bajaj Finance Ltd. are scheduled to announce results today.

The rupee strengthened 0.2% to 74.78 per U.S. dollar, while the yield on the 10-year benchmark government bond was little changed at 5.80%.

The Numbers

  • All but two of 19 sector sub-indexes compiled by BSE Ltd. advanced, led by a gauge of realty stocks
  • Reliance Industries Ltd. contributed the most to the Sensex advance, increasing 1.9% while Maruti Suzuki India Ltd. had the largest gain, rising 3.3%
  • Hindustan Unilever Ltd. was the biggest drag on the index and had the biggest drop, declining 0.5%

Related Stories

  • America’s Tech Stock Mania Draws in Amateur Traders From India
  • Fitch Solutions Lifts Palm Oil Price Forecast on Demand Recovery
  • Revving Tractor Sales Mask Indian Economy’s Deep Distress

©2020 Bloomberg L.P.

© Bloomberg. Pedestrians stand outside the Bombay Stock Exchange (BSE) building in Mumbai, India, on Monday, May 20, 2019. Indian stocks rallied the most in more than three years and the rupee and sovereign bonds climbed after exit polls signaled Prime Minister Narendra Modi’s ruling coalition is poised to retain power. Photographer: Dhiraj Singh/Bloomberg

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.